Search Results

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media Neuro-degenerative diseases , 16 (1-2), 95–110. https://doi.org/10.1159/000440864

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Neuro-degenerative diseases , 16 (1-2), 95–110. https://doi.org/10.1159/000440864

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://www.empowerbh.com /blog/what-are-neurodevelopmental-disorders/ [2] https://ourworldindata.org/neurodevelopmental-disorders

clinical study evaluating ANAVEX®3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication well-positioned to advance a competitive candidate into future studies aimed at addressing the ongoing and unmet medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

ET WHERE : Sandpiper Bay, South Florida WEBCAST LINK : http://noble.mediasite.com/mediasite/Play projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free:

Results showed that study participants with SIGMAR1 (rs1800866) or COMT (rs113895332/rs61143203) variants The additional exclusion of participants with the COMT variant resulted in a score improvement of +2.0 development towards individualized biomarker-guided targeted therapy for the right patient at the right time. https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Scott Gordon Core IR scottg@coreir.com Media

safely improve the symptoms of Rett syndrome is a high priority,” said Walter E Kaufmann, M.D., Chief Medical The full paper can be accessed online at: (https://www.sciencedirect.com/science/article/pii/S0091305719302515 About Rett Syndrome Rett syndrome is a devastating, non-inherited genetic post-natal progressive neurodevelopmental projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Email

(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://investors.evercore.com /news-releases/news-release-details/evercore-hosts-7th-annual-healthconx-conference-dec-3-5-2024

Company to host a webcast today at 8:30 a.m. Disease Patients ” to be available online as a preprint at medRxiv, and in submission to a peer-reviewed medical clinical study evaluating ANAVEX®3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most

Company to host a webcast today at 8:30 a.m. prolific author who has written and edited books on Alzheimer’s disease and has contributed to hundreds of medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics projected in any of such statements due to various factors, including the risks set forth in the Company’s most Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com [1] https://www.braincouncil.eu

Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients Data Confirm SIGMAR1 and COMT A significant impact on the drug response levels of both the SIGMAR1 (p<0.0080) and COMT (p<0.0014) genomic therapies, improves the efficacy and safety of patient treatment, reduces risks and drug development costs (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Scott Gordon Core IR scottg@coreir.com Media

Saunders specializes in representing emerging pharmaceutical, medical technology and biotechnology concerns practice, facilitated by his graduate studies in physiology at Case Western Reserve University and Albany Medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866